Galmed Pharmaceutica (GLMD)

$0.63 +0.01 (1.93%)
Market Cap 3.37M
Revenue (ttm) 0.00
Net Income (ttm) -10.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 139,400
Avg Vol 3,746,276
Day's Range N/A - N/A
Shares Out 5.48M
Stochastic %K 19%
Beta 0.47
Analysts Hold
Price Target $12.00

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 693 8448
Fax: 972 3 693 8447
Address:
16 Abba Hillel Road, Ramat Gan, Israel
madan_shatri
madan_shatri Apr. 24 at 2:14 PM
$GLMD lol anyone remember CEO's letter to SHs ? How much valuation is gone after that letter ? What did I say about such letters by CEOs of clinical biotech companies ? Its common modus of operandi
0 · Reply
ka1954
ka1954 Apr. 24 at 2:03 PM
$GLMD what a piece of crap !!! low volume fuck up
0 · Reply
getsometoday
getsometoday Apr. 23 at 11:33 PM
$GLMD join us next week for another gripping episode of pigs in space when ms piggy says Whaaaaaaattt!
0 · Reply
madan_shatri
madan_shatri Apr. 23 at 7:38 PM
$GLMD to me it appears that this decline is for reverse split now. As July 27 is approaching, this may now comtinue to decline until certain level of SP is achieved. IMO, pardon me if I am wrong, $0.30s or $0.4s could he the range MMs would be looking for to force RS. It may be a scam we won't know until the end game.
0 · Reply
ka1954
ka1954 Apr. 23 at 6:23 PM
$GLMD piece of crap. going down with only 78k volume, but went up 177m volume. what a turd
0 · Reply
getsometoday
getsometoday Apr. 23 at 5:44 PM
$GLMD she’s all set to rally now I sold. GLTA. You’re going to wake up tomorrow and this will be way up. You’re welcome.
1 · Reply
madan_shatri
madan_shatri Apr. 22 at 2:12 PM
$GLMD MMs won't let it implement RS at above $0.40s, JMHO. Unfortunately my sell mark $0.80s didn't come and finally it gave up knocking of $0.75 door. Slowly will start its usual daily 3% to 6% decline, may be from today until MM will achieve their RS target.
0 · Reply
madan_shatri
madan_shatri Apr. 22 at 11:21 AM
$GLMD It tried to break $0.75 mark everyday over the last 2 to 3 weeks amidst couple very heavy volume as well many decent volume days. No catalyst lined up for next few months, it needs to be seend if it can hold this level or the shorts accumulated over the last few weeks will cover slowly on low volume by bringing this down back to low $0.50s. Lets see ! Hopefully not but again, logic beats hopes !
0 · Reply
NomadsLand
NomadsLand Apr. 21 at 6:38 PM
$GLMD wake up one day at $5 -> $25 ->$150
1 · Reply
madan_shatri
madan_shatri Apr. 21 at 1:59 AM
$GLMD @Love_To_Learn are you Mo ? 😁😄😃😅🤣😂
2 · Reply
Latest News on GLMD
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Apr 14, 2026, 7:30 AM EDT - 11 days ago

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Galmed Stock Soars On Brain-Penetrating Aramchol Formulation

Apr 9, 2026, 11:04 AM EDT - 16 days ago

Galmed Stock Soars On Brain-Penetrating Aramchol Formulation

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Apr 9, 2026, 7:30 AM EDT - 16 days ago

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Mar 31, 2026, 4:15 PM EDT - 25 days ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jan 30, 2026, 4:15 PM EST - 3 months ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Dec 8, 2025, 8:30 AM EST - 4 months ago

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Dec 4, 2025, 8:30 AM EST - 5 months ago

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed Issues CEO Letter to Shareholders

Dec 1, 2025, 8:30 AM EST - 5 months ago

Galmed Issues CEO Letter to Shareholders

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 26, 2025, 8:30 AM EST - 5 months ago

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Nov 18, 2025, 8:30 AM EST - 5 months ago

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Nov 17, 2025, 8:30 AM EST - 5 months ago

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 28, 2025, 8:00 AM EDT - 8 months ago

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Aug 25, 2025, 7:30 AM EDT - 8 months ago

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 27, 2025, 8:00 AM EDT - 11 months ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 22, 2025, 8:00 AM EDT - 1 year ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

May 6, 2025, 7:30 AM EDT - 1 year ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Apr 2, 2025, 4:10 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Mar 20, 2025, 8:55 AM EDT - 1 year ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Apr 4, 2024, 5:06 PM EDT - 2 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Mar 15, 2024, 9:00 AM EDT - 2 years ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Nov 20, 2023, 4:32 PM EST - 2 years ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 14, 2023, 9:30 AM EDT - 3 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jul 10, 2023, 8:00 AM EDT - 3 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Jun 1, 2023, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

May 9, 2023, 7:00 AM EDT - 3 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Mar 29, 2023, 5:00 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Feb 8, 2023, 8:00 AM EST - 3 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Dec 14, 2022, 5:00 PM EST - 3 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Aug 4, 2022, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Jul 7, 2022, 8:27 AM EDT - 4 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 17, 2022, 7:30 AM EDT - 4 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

May 2, 2022, 7:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 28, 2022, 7:00 AM EDT - 4 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Apr 26, 2022, 8:30 AM EDT - 4 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 11, 2022, 7:30 AM EST - 4 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Jan 10, 2022, 9:14 AM EST - 4 years ago

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Galmed announces positive results of Phase 1 study of Amilo-5MER

Jan 10, 2022, 7:30 AM EST - 4 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Nov 8, 2021, 7:30 AM EST - 4 years ago

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Nov 8, 2021, 7:00 AM EST - 4 years ago

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Nov 1, 2021, 10:10 AM EDT - 4 years ago

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Oct 11, 2021, 8:00 AM EDT - 4 years ago

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Aug 19, 2021, 11:49 AM EDT - 5 years ago

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

madan_shatri
madan_shatri Apr. 24 at 2:14 PM
$GLMD lol anyone remember CEO's letter to SHs ? How much valuation is gone after that letter ? What did I say about such letters by CEOs of clinical biotech companies ? Its common modus of operandi
0 · Reply
ka1954
ka1954 Apr. 24 at 2:03 PM
$GLMD what a piece of crap !!! low volume fuck up
0 · Reply
getsometoday
getsometoday Apr. 23 at 11:33 PM
$GLMD join us next week for another gripping episode of pigs in space when ms piggy says Whaaaaaaattt!
0 · Reply
madan_shatri
madan_shatri Apr. 23 at 7:38 PM
$GLMD to me it appears that this decline is for reverse split now. As July 27 is approaching, this may now comtinue to decline until certain level of SP is achieved. IMO, pardon me if I am wrong, $0.30s or $0.4s could he the range MMs would be looking for to force RS. It may be a scam we won't know until the end game.
0 · Reply
ka1954
ka1954 Apr. 23 at 6:23 PM
$GLMD piece of crap. going down with only 78k volume, but went up 177m volume. what a turd
0 · Reply
getsometoday
getsometoday Apr. 23 at 5:44 PM
$GLMD she’s all set to rally now I sold. GLTA. You’re going to wake up tomorrow and this will be way up. You’re welcome.
1 · Reply
madan_shatri
madan_shatri Apr. 22 at 2:12 PM
$GLMD MMs won't let it implement RS at above $0.40s, JMHO. Unfortunately my sell mark $0.80s didn't come and finally it gave up knocking of $0.75 door. Slowly will start its usual daily 3% to 6% decline, may be from today until MM will achieve their RS target.
0 · Reply
madan_shatri
madan_shatri Apr. 22 at 11:21 AM
$GLMD It tried to break $0.75 mark everyday over the last 2 to 3 weeks amidst couple very heavy volume as well many decent volume days. No catalyst lined up for next few months, it needs to be seend if it can hold this level or the shorts accumulated over the last few weeks will cover slowly on low volume by bringing this down back to low $0.50s. Lets see ! Hopefully not but again, logic beats hopes !
0 · Reply
NomadsLand
NomadsLand Apr. 21 at 6:38 PM
$GLMD wake up one day at $5 -> $25 ->$150
1 · Reply
madan_shatri
madan_shatri Apr. 21 at 1:59 AM
$GLMD @Love_To_Learn are you Mo ? 😁😄😃😅🤣😂
2 · Reply
Love_To_Learn
Love_To_Learn Apr. 20 at 11:56 PM
$GLMD planted a cheat code on u lil algo switch 0.75pt clearance have to place it for 4am thank u for understanding folks
0 · Reply
getsometoday
getsometoday Apr. 20 at 5:44 PM
$GLMD 80 would be great
1 · Reply
Love_To_Learn
Love_To_Learn Apr. 20 at 2:49 PM
$GLMD LETS SHUFFLE 14.7 MILLION SHARES OFF THE BOOKS HERE FOLKS OFF 0.76*
2 · Reply
madan_shatri
madan_shatri Apr. 20 at 2:13 PM
$GLMD IMO there is one catalyst in May if they are on time. I think Ph1 study of Pharmacokinetics of Aramchol. This is the only known "possible catalyst" in mid May, they are on time. How big or irrelevant this data will be, we don't know. May be atleast in pre market there could be a tiny pump, who knows
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 20 at 1:17 PM
$GLMD AWAKENING YOUR 2.43 FILLER
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 20 at 11:31 AM
$GLMD WILL STOP PLAYING THE GAMES WITH U OK *
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 18 at 1:35 PM
$GLMD REAL VOLUME WAS 7.47 MILLION FRIDAY FYI NOT SUB 300K
1 · Reply
Love_To_Learn
Love_To_Learn Apr. 18 at 1:34 PM
$GLMD U WILL SEE SOME CHANGES STARTING MONDAY IN HER BEHAVIOUR SO IF U IN PAY ATTENTION
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 18 at 1:29 PM
$GLMD IVE BEEN MANIPULATING THE BID ASK AND VOLUME NUMBERS WITH IT THE MOVEMENT UNDER AND ABOVE 0.7 4 GOOD REASON. U WILL SEE WHY SHORTLY *
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 17 at 11:31 PM
$GLMD UPDATE PENDING
0 · Reply
getsometoday
getsometoday Apr. 17 at 8:29 PM
$GLMD what does it all mean!
1 · Reply
Love_To_Learn
Love_To_Learn Apr. 16 at 4:45 PM
$GLMD USING PBM HALT TO REV U UP A BIT OK
0 · Reply